GLP-1 Insurance Cutbacks Push Weight-Loss Marketers Into Brand Mode
As employers and insurers pull back GLP-1 coverage, drugmakers like Novo Nordisk and Eli Lilly are pivoting from awareness ads to brand-building for a growing out-of-pocket market.
What's changing
Employer coverage of GLP-1s for weight management has fallen from 72% in 2025 to 60% in 2026, with a further 10% of covering employers planning to drop it, according to data cited by Adweek. Cigna has cut GLP-1 weight-management coverage for its own employees while keeping diabetes coverage.
The marketing response is already visible. Novo Nordisk (Ozempic, Wegovy) moved its US media account to Omnicom to "scale consumer-focused strategies," a shift away from WPP. Eli Lilly launched an "A Life Covered" campaign via Wieden+Kennedy targeting Medicare beneficiaries through its GLP-1 Bridge Program.
Why awareness is no longer enough
In the coverage era, the marketing job was largely awareness: get people to ask their doctor, and insurance did the rest. As the safety net shrinks and more patients pay out of pocket, the job flips to justification and loyalty — convincing someone the product is worth their own money, and keeping them on it.
As Tracksuit's Sam Brough put it, brands that treat this "as a brand-building opportunity, not another awareness push" will pull ahead "in the out-of-pocket era." Our read: that is the whole game. Price sensitivity turns a category from demand generation into a brand-preference and retention contest.
The lesson beyond pharma
This pattern is not unique to weight-loss drugs. Any category facing subsidy or coverage cuts — from EV tax credits to wellness benefits — sees the same shift: when someone else stops paying, brand equity and retention become the growth levers, not reach.
Practically, marketers in exposed categories should rebalance now: shift spend from top-funnel awareness toward differentiation, proof of value and adherence or retention programmes. The brands that build genuine preference before the subsidy disappears will hold share; those still buying awareness will be discounting to keep it.
Quick FAQ
Why are weight-loss drug marketers changing strategy?
Employer GLP-1 coverage fell from 72% in 2025 to 60% in 2026, pushing more patients out of pocket and shifting marketing from awareness to brand-building and retention.
What are Novo Nordisk and Eli Lilly doing?
Novo moved its US media account to Omnicom for consumer-focused strategies; Lilly launched an 'A Life Covered' campaign via Wieden+Kennedy targeting Medicare beneficiaries.
What's the broader lesson?
When a subsidy or coverage shrinks in any category, brand equity and retention — not awareness — become the primary growth levers.
When insurance was paying, the job was awareness. When the patient pays, the job is preference and loyalty — and that's a brand contest, not a reach contest. Every marketer in a category facing subsidy cuts should be moving money toward differentiation and retention now, before the safety net goes. — Daniel Nikolla, Founder of Merx Marketing
When someone else stops paying, awareness stops working — brand equity and retention become the growth levers in any category losing its subsidy.
If a subsidy or benefit propping up your category disappeared tomorrow, would customers still choose you at full price?
If you would like to know more about this topic, please contact us on danieln@merxmarketing.co.uk
Sources: Adweek, MediaPost, Fierce Pharma.
Related reading
Written by Daniel Nikolla, Founder of Merx Marketing Ltd and Marketing Minute
Comments